Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Xofluza is an antiviral medicine for treating and preventing flu in adults and children from 1 year of age. The active substance in Xofluza, baloxavir marboxil, blocks an enzyme known as CEN (cap-dependent endonuclease), which the influenza virus uses to produce more copies of itself. By interfering with the activity of this enzyme, the medicine can treat the infection and prevent infection in patients exposed to the virus. 1
In Bangladesh Xofluza is approved for the following indications.2
Treatment of Influenza
XOFLUZA is indicated for the treatment of influenza in patients aged 1 year and above who have been symptomatic for no more than 48 hours (see section 3.1.2 Clinical/ Efficacy Studies).
XOFLUZA is indicated for treatment of influenza in patients aged 12 years and above who have been symptomatic for no more than 48 hours, and are at high risk of developing influenza complications.
Post-Exposure Prophylaxis of Influenza
XOFLUZA is indicated for the post-exposure prophylaxis of influenza in individuals aged 1 year and above.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Xofluza is available as
Tablets 40 mg
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Xofluza | European Medicines Agency [Internet; cited 2023, August 07]. Retrieved from:
xofluza-product-information-ro-7191686-november-2022